Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)
However, ethical risk communication also requires precision
DOI 10.1038/s41591-024-03018-2 This sub-study used body-composition imaging to work out how much of the weight change was fat rather than lean tissue
The weight loss timeline for tirzepatide provides a useful benchmark
[53] This increases the drug's binding to blood protein (albumin), which enables longer presence in the blood circulation
Frequently Asked Is this Ozempic or Wegovy